Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 15 Feb 2016

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

AiCuris is a Biotech company based on the Bayer Life Sciences park in Wuppertal (Germany). It is working on new anti-infective drugs and is a former spin-off of Germany’s biggest Pharma Company. It’s celebrating its 10th birthday this year, which is good reason to interview the CEO… So AiCuris is working on anti-infective drugs for […]

February 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 13 Feb 2016

What happened this week? 8 great innovators, PD-L1 combo, Genzyme

Monday: Here are 8 of Forbes’ Under 30 Year Olds Transforming European Biotech Tuesday: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type Wednesday: What’s the situation in France two weeks after the Trial Failure? Thursday: Why is Genzyme still Crazy Successful 5 Years after Sanofi’s Acquisition? Friday: World’s Largest Genome Sequencing Project partners […]

February 13, 2016 - 1 minutemin - By Philip Hemme

News and Trends 12 Feb 2016

Biotech of the week: Nordic Nanovector & its ARC technology

This week we say ‘au revoir’ to Nantes and head back up to the Scandinavian country that is Norway, in particular it’s capital city, Oslo – the location of our biotech of the week, Nordic Nanovector. City: Oslo, Norway Founded: 2009 Employees: +/- 30 (as off 11/15) Financial Data: €156M Market Cap (on 23/11/2015) CEO: Missions: Betalutin, a potential new treatment […]

February 12, 2016 - 1 minutemin - By Philip Hemme

News and Trends 10 Feb 2016

“Actelion could be the First European-born Biopharma to make it to the Major League”

This is what the founder & CEO Jean-Paul Clozel of Actelion (Switzerland) said at the announcement of the 2015 financial results for the company. And it’s definitely true. Actelion is the only European born biopharma to have over 1K employees (in fact over 2,547 of them). This is already a big achievement but not their greatest… For example, in 2015, […]

February 10, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 9 Feb 2016

When the Biggest Tech Investors Go Wild for Biotech

Biotech is catching new investors’ interest. Just in 2015, Google Ventures, the accelerator Y Combinator, Andreessen Horowitz (one of the most successful early-stage investment funds in the Valley) and Peter Thiel (founder of Paypal) showed their interest in Biotech. Why? And why now? Andreessen Horowitz is the investment fund created by Marc Andreessen (founder of Netscape) and […]

February 9, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 7 Feb 2016

What happened this week? CRISPR, Microbiome, Algae in Biotech

Monday: Huge Milestone: UK Approves CRISPR Editing on Human Embryos Tuesday: Ultimate Review: The Unlimited Biotech Potential of Algae Wednesday: Meet the CEO of Europe’s Leading Microbiome Biotech Thursday: Zika Virus: Who in Biotech is Working to Stop its Spread? Friday: German RNA Specialist Could Break French Biotech into the Cancer Ecosystem Bonus: How we […]

February 7, 2016 - 1 minutemin - By Philip Hemme

News and Trends 5 Feb 2016

Biotech of the week: Effimune, the French Success-story in autoimmune disease

This week, we leave central Spain and head North-East, across the Pyrenees and head to the largest city in ‘Traditional Brittany’, France, and also the this week’s location, Nantes. This picturesque city was voted the most Green in EU (2013), is famous for the production of Muscadet wine and is home to our biotech of […]

February 5, 2016 - 2 minutesmins - By Philip Hemme

Inside Labiotech 4 Feb 2016

How we Raised our First Seed Round to Build the Next TechCrunch for Biotech

You may have read it on Tech.eu (the biggest EU Startup blog), Gründerszene (the biggest German startup magazine) or in Maddyness (the biggest French Startup magazine) yesterday: Yes, we raised our first seed fundraising to become ‘the next TechCrunch’ for Biotech! The 6-figure seed round was raised with our lead investor WestTech Ventures as well as 4 European business […]

February 4, 2016 - 6 minutesmins - By Philip Hemme

pierre fabre fund innovation biotech pharma

News and Trends 3 Feb 2016

France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation

Open Innovation is now everywhere, even Pharma. So, just today in France, the opening of the Pierre Fabre Fund for Innovation for biotech startups has been announced. Most Big Pharma have their own program. Boehringer-Ingelheim for example is partnering with BioMedX to run a new program with researchers from Heidelberg. Now the 3rd largest Pharma company in France, […]

February 3, 2016 - 2 minutesmins - By Philip Hemme

enterome pierre belichard microbiome crohns ibd

News and Trends 3 Feb 2016

Meet the CEO of Europe’s Leading Microbiome Biotech

We met Pierre Belichard, the CEO of Enterome, last week to discuss the increasingly famous trend in the Human Microbiome and how this is impacting therapeutics in Crohn’s disease, the understanding of Medical Microbiomics and investment in this field of Biotech. Enterome, established in 2012, is a French biotech that is hot at the moment, […]

February 3, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 1 Feb 2016

Huge Milestone: UK Approves CRISPR Editing on Human Embryos

This could be a HUGE game-changer for Europe’s research on stem cells, and more broadly Gene Editing…. Research on human embryos is a very touchy subject. And when you want to allow the use of the most powerful gene-editing tool on them, it’s becomes even touchier. Research on human embryos has been forbidden almost everywhere (with exception to China […]

February 1, 2016 - 3 minutesmins - By Philip Hemme

oxford biotech biomedica novartis car t cancer

News and Trends 1 Feb 2016

World CAR-T Leader Starts New Program with a UK Biotech

Pretty impressive CAR-T news coming from across the Channel… Oxford BioMedica just launched a second collaboration with Novartis, which has shown tremendous Phase II results – and the most advanced in CAR-T therapy in development so far (read our review on how CAR-T works and who else is working the field). This collaboration covers the […]

February 1, 2016 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

What happened this week? 8 great innovators, PD-L1 combo, Genzyme

Biotech of the week: Nordic Nanovector & its ARC technology

“Actelion could be the First European-born Biopharma to make it to the Major League”

When the Biggest Tech Investors Go Wild for Biotech

What happened this week? CRISPR, Microbiome, Algae in Biotech

Biotech of the week: Effimune, the French Success-story in autoimmune disease

How we Raised our First Seed Round to Build the Next TechCrunch for Biotech

France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation

Meet the CEO of Europe’s Leading Microbiome Biotech

Huge Milestone: UK Approves CRISPR Editing on Human Embryos

World CAR-T Leader Starts New Program with a UK Biotech

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!